BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its ...
Innovative collaboration advances the development of novel gene therapies for patients by providing coordinated services across Forge’s leading AAV manufacturing capabilities and Labcorp’s scientific ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
Predictive Oncology Inc. has announced the successful development of 3D organoid models specifically for Labcorp, which include unique human and rat liver toxicity models. These models are designed to ...
As a leading independent diagnostic laboratory, LabCorp participates in a highly attractive duopoly that offers bright prospects as healthcare moves toward reformed payment models, despite current ...
Laboratory Corporation of America Holdings LH or LabCorp inked a strategic collaboration deal with Ascension – a U.S.-based Catholic and non-profit health system to expand patient access to LabCorp’s ...
April 25 (Reuters) - Laboratory Corp of America Holdings (LH.N), opens new tab missed estimates for quarterly profit on Tuesday, as its drug development unit struggled against curbs on animal imports, ...
Health and physician system leaders are facing unprecedented challenges while operating in an ever-evolving healthcare landscape. In support of Labcorp’s mission to improve health and improve lives, ...
The positions in the table below reflect the Labcorp Drug Development's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results